Remarkably, functionalized macrophage membranes showcase the advantages of personalized cancer treatment, as the extracellular antibody domains specifically bind to HER2 receptors to target and eliminate HER2+ breast cancer cells, while facilitating efficient drug delivery. This evidence concerns the gene ERBB2 and breast carcinoma.